SOURCE: Amarillo Biosciences, Inc.

November 15, 2006 11:28 ET

Amarillo Biosciences Reports Findings From Influenza Study at Trudeau Institute

Study Confirms Efficacy of Oral Interferon as Therapeutic Agent Against Influenza

AMARILLO, TX -- (MARKET WIRE) -- November 15, 2006 --Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has received a final report on a study performed at the renowned Trudeau Institute of Saranac Lake, New York, entitled "Low Dose Oral Interferon Alpha Reduces Morbidity and Promotes Recovery from Influenza." The study examined the effects of low dose oral interferon alpha on four groups of mice challenged with influenza virus. The four groups were orally administered doses of 0, 1, 10, or 100 International Units (IU) of interferon for seven days before and 7 days after the influenza challenge. The mice receiving 10 IU and 100 IU of interferon lost less weight and had lower influenza viral titers than those in the placebo group (receiving no interferon) or the extremely low dose (1 IU) group. Prevention of weight loss in mice is a key indicator of a successful therapeutic agent in influenza studies.

The results suggest that oral IFN, administered at the proper dose, acts directly on the nasal and tracheal epithelial cells to induce an anti-viral state, which suppresses viral replication in the upper respiratory tract. Because of these findings, the Company has agreed to fund additional research at the Trudeau Institute to further support the Company's position that oral interferon will have a major role to play in addressing the impending influenza pandemic.

Other influenza studies in mice sponsored by the Company are being conducted by Manfred Beilharz, PhD, the Head of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, the University of Western Australia. Dr. Beilharz and members of his research department have 10 publications and 3 dissertations on the subject of orally administered interferon. Dr. Beilharz is the past President of the Australian Interferon Society and a world-renowned expert on interferon. Dr. Beilharz recently reported that a dose of 100 IU of interferon was beneficial in mice but a dose of 10,000 IU was not beneficial, thereby suggesting a bell-shaped response curve to oral interferon.

Amarillo Biosciences has previously announced that it intends to fund a human influenza trial conducted by Dr. Beilharz. The trial will test whether daily dosing with oral interferon can protect human volunteers from infection and reduce the severity of respiratory tract infections, compared to placebo. The study is expected to start in Australia in mid 2007 and continue for 6 months during which time 200 volunteers are expected to naturally encounter influenza viruses and other respiratory tract pathogens.

"It is encouraging that quality research laboratories in the US and Australia are obtaining similar results showing that oral interferon may have a role to play in controlling influenza virus," said Dr. Joseph Cummins, CEO and President of Amarillo Biosciences, Inc. Nearly 50 years ago scientists in England reported that an antiviral protein found in chicken embryos was inhibiting influenza virus. This "interfering" protein was called "interferon." "We have known for nearly 50 years that interferon inhibits influenza virus. Now we are working to establish an oral dose of interferon that can be used to help control influenza virus," said Dr. Joseph Cummins.

It has been published that low-dose oral interferon is safe and beneficial in the treatment of other human diseases such as measles, multiple sclerosis, hepatitis B and Sjogren's syndrome.

About the Trudeau Institute

The Trudeau Institute, Inc. is one the nation's leading independent biomedical research centers. Its mission is to make breakthrough discoveries that lead to improved human health. More information on the organization is available from its annual report, which is available on the Institute's website

About Amarillo Biosciences, Inc. (

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301